OLBA HEALTHCARE HOLDINGS,Inc. FY2026 Q2 Earnings Report

Quick View

Executive Summary

FY2026 Q2 consolidated results achieved modest top-line growth with Revenue of ¥624.4B (YoY +¥18.1B +3.0%), but profits fell significantly: Operating Income ¥6.7B (YoY -¥1.4B -16.6%), Ordinary Income ¥6.8B (YoY -¥1.4B -18.0%), and Net Income ¥4.5B (YoY -¥2.0B -30.5%). Gross profit margin remained at 11.1%, with SG&A expenses of ¥62.7B absorbing most of gross profit of ¥69.4B, resulting in a low Operating Margin of 1.1% that underscores a low-profitability structure. By segment, the Medical Devices Business posted Revenue of ¥589.2B and Operating Income of ¥5.6B, the SPD Business recorded Revenue of ¥30.3B and Operating Income of ¥0.6B, and the Nursing Care Products Business reported Revenue of ¥14.6B and Operating Income of ¥1.2B. Full-year guidance is maintained at Revenue of ¥1279.8B (YoY +4.3%), Operating Income of ¥20.0B (YoY +1.0%), and Net Income of ¥13.2B (YoY -1.7%), implying profitability improvement in H2.

Key Financial Metrics

[Profitability] ROE 3.7% (down YoY); Operating Margin at a low 1.1%; Net Margin at 0.7% highlights vulnerability in the earnings structure. ROIC stands at 3.4%, indicating low returns on invested capital. EBITDA margin is a limited 1.7%. [Cash Quality] Cash and cash equivalents ¥29.2B; Operating Cash Flow (OCF) -¥7.7B, which turned negative relative to Net Income of ¥4.5B, indicating challenges in cash conversion. Free Cash Flow is -¥17.5B, indicating an inability to internally fund investments. Cash conversion rate (OCF/EBITDA) -0.75x, and Operating CF/Net Income -1.71x, raising concerns about earnings quality. Short-term liability coverage (Cash/Short-term liabilities) 1.24x, suggesting limited liquidity headroom. [Investment Efficiency] Total asset turnover 1.30x; Capex ¥10.5B equals 2.98x depreciation of ¥3.5B, indicating continued aggressive investment. Fixed asset turnover 3.19x; Accounts receivable days 70 days; Inventory days 67 days. [Financial Soundness] Equity Ratio 25.3%; Current ratio 119.5%; Quick ratio 96.6%, indicating only limited liquidity buffer. Debt-to-Equity Ratio 2.96x reflects a high-leverage structure. Short-term borrowings surged to ¥23.5B from ¥4.0B in the prior-year Q2 (+487.4%), and a short-term liabilities ratio of 64.1% elevates maturity mismatch risk. Debt/EBITDA 3.58x; Interest coverage 8.98x.

Cash Flow Analysis

Operating CF was -¥7.7B, turning negative against Net Income of ¥4.5B, with Operating CF/Net Income at -1.71x, failing to confirm cash backing for earnings. The primary driver was working capital absorption: increases in accounts receivable of ¥239.7B and electronically recorded monetary claims of ¥36.9B, along with inventory build of ¥53.2B, constrained liquidity. While accounts payable increased by ¥11.4B, partially offsetting via extended payment terms, overall working capital management remains an issue. Investing CF was -¥9.8B, mainly due to Capex of ¥10.5B, continuing an investment pace roughly three times depreciation of ¥3.5B. Financing CF details are limited for the quarter, but short-term borrowings rose significantly YoY by +¥19.5B, strengthening funding. Shareholder returns included dividend payments of ¥4.9B and share buybacks of ¥1.4B, exerting pressure on capital allocation amid Free CF of -¥17.5B. Cash and cash equivalents stand at ¥29.2B, covering short-term liabilities of ¥23.5B at 1.24x, which is limited; continued negative Operating CF could heighten refinancing risk.

Quality of Earnings

With Ordinary Income at ¥6.8B and Operating Income at ¥6.7B, net non-operating income was a modest +¥0.1B. Non-operating income mainly comprises financial income such as dividends received and interest income, but is negligible relative to Revenue, indicating heavy reliance on operating activities. Net extraordinary gains/losses were +¥0.2B, with minor impact beyond ordinary operations. Operating CF of -¥7.7B fell well below Net Income, raising accrual-based concerns about earnings quality. As working capital expansion indicates, increases in receivables and inventory are widening the timing gap between profit recognition and cash collection. With a low Operating Margin of 1.1%, even slight cost increases or pricing pressure can easily compress profits, exposing structural fragility as a qualitative risk. Against EBITDA of ¥10.2B, interest paid was ¥0.8B, resulting in interest coverage of 8.98x; while interest burden is manageable, the persistence of a low-profit structure poses sustainability challenges.

Risk Factors

1. Risk of persistent low-profit structure: With Operating Margin at 1.1% and Net Margin at 0.7%, profitability is extremely low; intensifying price competition or rising costs could further compress profits. With an EBIT margin in the 1% range, resilience to economic fluctuations is weak, making structural improvement urgent.
2. Dependence on short-term funding and liquidity risk: Short-term borrowings surged to ¥23.5B (+487% YoY), with a short-term liabilities ratio of 64.1%, highlighting a pronounced maturity mismatch. If negative Operating CF persists, cash of ¥29.2B may be insufficient, and refinancing and interest rate risks could constrain financial flexibility.
3. Funding pressure from deteriorating working capital efficiency: Increases in receivables and inventory drove Operating CF to -¥7.7B; delays in working capital collection and inventory stagnation are straining liquidity. Continued Capex of ¥10.5B (3x depreciation) and shareholder returns of ¥6.3B will require fundamental improvements in working capital management.

Industry Benchmark (Reference - Our Research)

[Position within the industry] (Reference information - our research) Over the past five fiscal periods, the Operating Margin was 1.1% (FY2026 Q2), trending flat to slightly down versus recent levels, and there is no confirmation of margin improvement against a Revenue growth rate of 3.0%. The Net Margin of 0.7% also remains low. The Company, engaged in medical device wholesale and SPD operations, has a low-gross-margin, high-volume business model; while Operating Margins of a few percent are typical for the industry, a level in the 1% range likely places it in the lower tier. The Equity Ratio of 25.3% is within the standard range for wholesalers, but D/E of 2.96x is on the high-leverage side. ROE of 3.7% is estimated to be below the industry average and trending down versus the Company’s history. While the 3.0% Revenue growth rate indicates modest growth, converting it into profit growth remains a challenge. Although limited benchmark data makes definitive comparisons difficult, the Company appears to have ample room to improve profitability and efficiency and shows a high dependence on financial leverage. (Note: Comparison set: Company’s past five fiscal periods; Source: our compilation)

Key Takeaways from Results

1. Negative turn in Operating CF and challenges in working capital management: Operating CF of -¥7.7B significantly undercut Net Income of ¥4.5B, with receivables and inventory increases absorbing cash. Deterioration in working capital efficiency observable from the results indicates that improving the collection cycle and optimizing inventory are priority issues.
2. Surge in short-term borrowings and refinancing response: Short-term borrowings increased from ¥4.0B to ¥23.5B (+487%), with a short-term liabilities ratio of 64.1%, indicating pronounced maturity concentration. While maintaining a high Payout Ratio of 111.1% and shareholder returns, rising dependence on borrowings suggests a need to reassess capital allocation priorities.
3. Gap between aggressive investment and low ROIC: The Company continues growth investments with Capex of ¥10.5B (3x depreciation), yet ROIC remains at 3.4%. While investment effects may take time to materialize, profitability improvement and higher investment returns in H2 and beyond are key to achieving full-year guidance.

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not constitute a recommendation to invest in any specific security. The industry benchmark is reference information compiled by our company based on publicly available financial statements. Investment decisions are your own responsibility; please consult a professional as necessary before making any decisions.